Evidence map›Paper›PMID 36144982›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Sorafenib-Loaded Cu

An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Multifunctional CuFrontiers in chemistry · 2026
    Review
  2. Article
  3. Review
  4. Glucose-Regulated Protein 78 Targeting ICG and DOX Loaded Hollow FeInternational journal of nanomedicine · 2024
    Article
  5. Plasmonic CuNanomaterials (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

An-Tian HuangInstitute of Bismuth and Rhenium, School of Materials and Chemistry, Shanghai Collaborative Innovation Center of Energy Therapy for Tumors, University of Shanghai for Science and Technology, Shanghai 200093, China.
Jun DuInstitute of Bismuth and Rhenium, School of Materials and Chemistry, Shanghai Collaborative Innovation Center of Energy Therapy for Tumors, University of Shanghai for Science and Technology, Shanghai 200093, China.
Zhi-Yong LiuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Guang-Cong ZhangDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Weinire AbuduwailiDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Jia-Yan YanDepartment of Liver Surgery and Transplantation, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Jia-Lei SunDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.ORCID 0000-0002-4021-5079
Ru-Chen XuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Tao-Tao LiuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Xi-Zhong ShenDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Ling DongDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.ORCID 0000-0001-5995-7673
Ji-Min ZhuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China.ORCID 0000-0002-2150-473X
Yuhao LiInstitute of Bismuth and Rhenium, School of Materials and Chemistry, Shanghai Collaborative Innovation Center of Energy Therapy for Tumors, University of Shanghai for Science and Technology, Shanghai 200093, China.ORCID 0000-0001-7146-8645
Sun Yat-sen University · CNUniversity of Shanghai for Science and Technology · CNFudan University · CNShanghai Medical College of Fudan University · CN

Funding

National Natural Science Foundation of China 21501121National Natural Science Foundation of China 81472673National Natural Science Foundation of China 81672334National Natural Science Foundation of China 81672720Natural Science Foundation of Shanghai 19ZR1434700Natural Science Foundation of Shanghai 22ZR1411800
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) accounts for the predominant form of liver malignancy and presents a leading cause of cancer-related death globally. Sorafenib (SOR), a first-line targeted drug for advanced HCC treatment, has a battery of untoward side effects. Photothermal therapy (PTT) has been utilized as an effective adjuvant in synergy with other approaches. However, little is known about the tumoricidal efficacy of combining SOR with PTT for HCC. Herein, a novel versatile nanoparticle, Cu

Indexed as

copper(I) selenidehepatocellular carcinomaphotothermal therapysorafenibsynergistic therapy

Identifiers

PMID36144982
PMCPMC9505850
OpenAlexW4295941840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.